[Corrigendum] In vitro and in vivo activities of an antitumor peptide HM-3: A special dose-efficacy relationship on an HCT‑116 xenograft model in nude mice
- Sitelbanat Yassin
- Jialiang Hu
- Hanmei Xu
- Ce Li
- Sarra Setrerrahmane
Affiliations: The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China
- Published online on: February 13, 2020 https://doi.org/10.3892/or.2020.7503
Copyright : © Yassin
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License [CC BY 4.0].
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
After the publication of the article, the authors have realized that Figs. 3 and 7 in their paper were published with errors; in the first instance, regarding Fig. 3, panels ‘C’ and ‘D’ contained partially overlapping data and were derived from the same original source, where these images were intended to show the effect of 2 ng/ml sunitinib and 2 µg/ml HM‑3, respectively, on cell migration. Likewise, in Fig. 7, panels ‘C’ and ‘D’ also contained partially overlapping data derived from the same original source, even though these images were intended to show representative images for sections of tumor tissue from the HM‑3 (3 mg/kg) and HM‑3 (48 mg/kg) treatment groups. These errors arose inadvertently, as a consequence of the authors' mishandling of their data. The revised versions of Figs. 3 and 7, featuring the corrected data panels for panels ‘C’ and ‘D’ in both Figures, are shown opposite. The revised data shown for these Figures do not affect the overall conclusions reported in the paper. The authors apologize to the Editor of Oncology Reports and to the readership for any inconvenience caused. [the original article was published in Oncology Reports 36: 2951‑2959, 2016; DOI: 10.3892/or.2016.5077].